Drug Trial Radar · NCT06280144
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
6,080
Planned (sponsor's estimate)
Start
Sep 22, 2023
Primary completion
Jun 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Changchun BCHT Biotechnology Co.Industry
- Sponsor type
- Industry
- Collaborators
- Hu Bei province Center for Disease control and prevention; The Inner Mongolia Autonomous Region Center for Disease Control and Prevention
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.
Conditions
- Influenza Prevention
Interventions
Influenza Vaccine, Live, Nasal, Freeze-driedBiological
The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
Sterile water for inhalationOther
Sterile water for inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary influenza protective effect endpointTime frame: 7 months
- Primary influenza protective effect endpointTime frame: 7 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Chifeng, Inner Mongolia, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.